このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Kancera マネジメント

マネジメント基準チェック /14

Kancera'sの CEO はPeter Selinで、 Jul2023年に任命され、の在任期間は 1.08年です。は、会社の株式の0.026%を直接所有しており、その価値はSEK 54.99K 。経営陣と取締役会の平均在任期間はそれぞれ1.1年と12.6年です。

主要情報

Peter Selin

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.3yrs
CEOの所有権	0.03%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	12.8yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Peter Selin (51 yo)

1.3yrs

在職期間

Mr. Peter Selin serves as Chief Executive Officer of Kancera AB (publ) since July 1, 2023. He had been an Executive Vice president of Corporate Development & Finance at Kancera AB (publ) since May 01, 2022...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Thomas Olin	Executive VP & Director	less than a year	SEK 3.57m	0.30% SEK 690.9k
Peter Selin	Chief Executive Officer	1.3yrs	データなし	0.026% SEK 59.6k
Hans Richter	Chief Financial Officer	no data	データなし	データなし
Robert Edfors	Chief Scientific Officer & Senior Vice President of Clinical Development	less than a year	データなし	データなし
Niclas Brynne	Head of Clinical Development	no data	データなし	0.024% SEK 55.2k
Markus Jerling	Chief Medical Officer	1.1yrs	データなし	データなし

0.6yrs

平均在職期間

66yo

平均年齢

経験豊富な経営陣: KANの経営陣は経験豊富とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Thomas Olin	Executive VP & Director	14.8yrs	SEK 3.57m	0.30% SEK 690.9k
Charlotte Edenius	Independent Director	8.3yrs	SEK 125.00k	0% SEK 0
Håkan Mellstedt	Independent Director	14.8yrs	SEK 125.00k	0.17% SEK 407.8k
Erik Nerpin	Independent Chairman of the Board	14.8yrs	SEK 175.00k	0.24% SEK 555.6k
Carl-Henrik Heldin	Independent Director	12.8yrs	SEK 125.00k	0.066% SEK 153.9k
Anders Gabrielsen	Independent Director	6.2yrs	SEK 125.00k	データなし
Petter Brodin	Independent Director	3.4yrs	SEK 75.00k	データなし

12.8yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: KANの取締役会は経験豊富で経験豊富です ( 12.4年の平均在任期間)。

Kancera マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Insufficient new directors

Recent updates

Kancera AB (Publ) Provides Operational Update Concerning Its Clinical Development Program

New minor risk - Share price stability

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Kancera AB's Fractal Study Results to Be Presented at the ESC 2024 Conference

New major risk - Financial position

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14